1. Inicio
  2. Publicaciones
  3. Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography

Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Carot-Sierra, JM
  • Villalba-Ortiz, A
  • Siddiqi, H
  • Vallejo-Vigo, RM
  • Lara-Romero, C
  • Martin-Fernandez, M
  • Fernandez-Paton, M
  • Alfaro-Cervello, C
  • Crespo, A
  • Coello, E
  • Merino-Murgui, V
  • Madamba, E
  • Benlloch, S
  • Puglia, V
  • Ferrandez, A
  • Monton, C
  • Escudero-Garcia, D
  • Lluch, P
  • Aller, R
  • Loomba, R
  • Romero-Gomez, M

Grupos

Abstract

BACKGROUND AND AIMS: A noteworthy proportion of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) have an indeterminate vibration-controlled transient elastography (VCTE). Among these patients, we aimed to identify candidates for MASLD treatment by diagnosing significant fibrosis. METHODS: This was a real-world prospective study including a large dataset of MASLD patients with paired VCTE and liver biopsy from 6 centers. A total of 1196 patients were recruited and divided in training (3 centers, Spain), internal validation (2 centers, Spain), and external validation (1 center, United States) cohorts. In patients with indeterminate liver stiffness measurement (LSM) (8-12 kPa), a diagnostic algorithm was developed to identify significant fibrosis, defined as histological stage >= F2. Statistical analysis was performed using Gaussian mixture model (GMM) and k-means unsupervised clusterization. RESULTS: From the eligible population, 33%, 29%, and 31% had indeterminate VCTE in the training, internal and external validation samples, respectively. The controlled attenuation parameter allowed the differentiation of GMM clusters with a cutoff of 280 dB/m (area under the curve, 0.89; 95% confidence interval, 0.86-0.97). Within patients with <280 dB/m, a LSM between 8.0-9.0 kPa showed a 93% sensitivity and a 91% negative predictive value to exclude significant fibrosis. Among patients with >= 280 dB/m, a LSM between 10.3 and 12.0 kPa diagnosed significant fibrosis with a 91% specificity. Applying this algorithm to the validation cohorts, 36% of the indeterminate VCTE were reallocated. The reallocated high-risk group showed a prevalence of 86% significant fibrosis, opening the therapeutic window for MASLD patients. CONCLUSIONS: To identify candidates for MASLD treatment among indeterminate VCTE, an algorithm-based on the sequential combination of LSM and controlled attenuation parameter thresholds can optimize the diagnosis of moderate-to-advanced fibrosis.

Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1542-3565, 1542-7714

Clinical Gastroenterology and Hepatology  ELSEVIER SCIENCE INC

Tipo:
Article
Páginas:
1183-11935
PubMed:
39551253
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,691 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 9

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Stiffness Measurement; Controlled Attenuation Parameter; Significant Fibrosis

Cita

Compartir